29-Jan-2026
No headlines found.
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
Business Wire (Tue, 27-Jan 8:00 AM ET)
AI Diagnostics: The End of the High-Cost Imaging Era
Globe Newswire (Fri, 16-Jan 11:40 AM ET)
Business Wire (Mon, 12-Jan 10:21 AM ET)
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
Business Wire (Wed, 17-Dec 8:00 AM ET)
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
Business Wire (Thu, 11-Dec 8:00 AM ET)
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
Business Wire (Tue, 18-Nov 8:00 AM ET)
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Atricure trades on the NASDAQ stock market under the symbol ATRC.
As of January 29, 2026, ATRC stock price declined to $36.95 with 455,642 million shares trading.
ATRC has a beta of 0.45, meaning it tends to be less sensitive to market movements. ATRC has a correlation of 0.05 to the broad based SPY ETF.
ATRC has a market cap of $1.84 billion. This is considered a Small Cap stock.
Last quarter Atricure reported $134 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.10.
In the last 3 years, ATRC traded as high as $59.61 and as low as $18.94.
The top ETF exchange traded funds that ATRC belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
ATRC has underperformed the market in the last year with a price return of -12.9% while the SPY ETF gained +16.5%. However, in the short term, ATRC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +4.3% vs +1.3% return in SPY. But in the last 2 weeks, ATRC shares have been beat by the market, returning -10.9% compared to an SPY return of +0.3%.
ATRC support price is $36.58 and resistance is $38.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATRC shares will trade within this expected range on the day.